Clinical Trial Data for Perforomist (Formoterol Fumarate)
Inhalation Solution Presented at International ATS Conference
-- New product recently approved by FDA for long-termmaintenance treatment of COPD bronchoconstriction; data demonstratefirst nebulized formoterol fumarate provides improved lung functioncomparable to dry powder formoterol, enhanced patient quality oflife, and positive safety profile -- NAPA, CA (May 20, 2007) – Data presented at theInternational Conference of the American Th...
Clinical Trial Data for Perforomist (Formoterol Fumarate)
Inhalation Solution Presented at International ATS Conference
-- New product recently approved by FDA for long-term maintenancetreatment of COPD bronchoconstriction; data demonstrate firstnebulized formoterol fumarate provides improved lung functioncomparable to dry powder formoterol, enhanced patient quality oflife, and positive safety profile -- NAPA, Calif., May 20, 2007 /PRNewswire/ -- Data presented at theInternational Conference of the America...
Clinical Trial Data for Perforomist Inhalation Solution to be
Presented at ATS on May 20, 2007
-- Data from Phase III pivotal trial demonstrate safety andefficacy of first FDA-approved nebulized formoterol fumarate forpatients with moderate to severe COPD -- NAPA, Calif., May 16, 2007 /PRNewswire/ -- Dey, L.P. announcedthat two clinical data presentations will be given at theInternational Conference of the American Thoracic Society (ATS) onSunday, May 20, at the Moscone Center in S...